Avis Michelle Davenport

Array ( [id] => 14712903 [patent_doc_number] => 20190247515 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => ANTIBODY-MEDIATED AUTOCATALYTIC, TARGETED DELIVERY OF NANOCARRIERS TO TUMORS [patent_app_type] => utility [patent_app_number] => 16/310372 [patent_app_country] => US [patent_app_date] => 2017-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32667 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16310372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16012881 [patent_doc_number] => 20200181283 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => PRL3 ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/309439 [patent_app_country] => US [patent_app_date] => 2017-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28595 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16309439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14582021 [patent_doc_number] => 20190218619 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => Composition for diagnosing cancer using potassium channel proteins [patent_app_type] => utility [patent_app_number] => 16/307972 [patent_app_country] => US [patent_app_date] => 2017-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7870 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16307972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18701349 [patent_doc_number] => 11787848 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-17 [patent_title] => CD33 specific chimeric antigen receptors [patent_app_type] => utility [patent_app_number] => 15/616869 [patent_app_country] => US [patent_app_date] => 2017-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 60 [patent_no_of_words] => 41796 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 240 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15616869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16376374 [patent_doc_number] => 20200325216 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => AB6 FAMILY DESIGNER LIGANDS OF TGF-BETA SUPERFAMILY [patent_app_type] => utility [patent_app_number] => 16/305771 [patent_app_country] => US [patent_app_date] => 2017-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23079 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 865 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16305771 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16361041 [patent_doc_number] => 20200317792 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => ANTIBODIES AND METHODS OF MAKING SAME [patent_app_type] => utility [patent_app_number] => 16/303530 [patent_app_country] => US [patent_app_date] => 2017-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10619 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16303530 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14312555 [patent_doc_number] => 20190145981 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => METHODS FOR DETERMINING DPP3 AND THERAPEUTIC METHODS [patent_app_type] => utility [patent_app_number] => 16/095563 [patent_app_country] => US [patent_app_date] => 2017-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23372 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16095563 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18369130 [patent_doc_number] => 11649284 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-16 [patent_title] => Cancer gene therapy targeting CD47 [patent_app_type] => utility [patent_app_number] => 16/094416 [patent_app_country] => US [patent_app_date] => 2017-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 23 [patent_no_of_words] => 15007 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16094416 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15345335 [patent_doc_number] => 20200010559 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => BINDING MOLECULES TO CD38 AND PD-L1 [patent_app_type] => utility [patent_app_number] => 16/088181 [patent_app_country] => US [patent_app_date] => 2017-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12287 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16088181 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17008542 [patent_doc_number] => 20210239703 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => PD1 AND PDL-1 EXPRESSION DURING PROGRESSION FROM MYELODYSPLASTIC SYNDROME TO ACUTE MYELOGENOUS LEUKEMIA [patent_app_type] => utility [patent_app_number] => 16/081229 [patent_app_country] => US [patent_app_date] => 2017-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5920 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16081229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15556871 [patent_doc_number] => 20200062847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => RECOMBINANT ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1) AND USES THEREFOR [patent_app_type] => utility [patent_app_number] => 16/488667 [patent_app_country] => US [patent_app_date] => 2017-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7183 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16488667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17938436 [patent_doc_number] => 11472877 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-18 [patent_title] => Anti-TREM1 antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/078965 [patent_app_country] => US [patent_app_date] => 2017-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 93 [patent_figures_cnt] => 56 [patent_no_of_words] => 86670 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16078965 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13901863 [patent_doc_number] => 20190040136 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => ANTI-LAG-3 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/079947 [patent_app_country] => US [patent_app_date] => 2017-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25784 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -58 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16079947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16831024 [patent_doc_number] => 11007255 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-18 [patent_title] => Cancer vaccines and methods of treatment using the same [patent_app_type] => utility [patent_app_number] => 16/075527 [patent_app_country] => US [patent_app_date] => 2017-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 21520 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16075527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16635306 [patent_doc_number] => 10913801 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-09 [patent_title] => PD-1 antibodies [patent_app_type] => utility [patent_app_number] => 16/073942 [patent_app_country] => US [patent_app_date] => 2017-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7225 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16073942 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13622205 [patent_doc_number] => 20180362654 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => Methods for Reducing or Preventing Growth of Tumors Resistant to EGFR and/or ErbB3 Blockade [patent_app_type] => utility [patent_app_number] => 16/061102 [patent_app_country] => US [patent_app_date] => 2016-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16993 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16061102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18302066 [patent_doc_number] => 11623957 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-11 [patent_title] => Heterodimeric antibodies that bind CD3 and PSMA [patent_app_type] => utility [patent_app_number] => 16/489539 [patent_app_country] => US [patent_app_date] => 2016-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 39 [patent_no_of_words] => 25720 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16489539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15618915 [patent_doc_number] => 20200079862 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-12 [patent_title] => ANTI-OX40 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/781047 [patent_app_country] => US [patent_app_date] => 2016-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46409 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15781047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17875556 [patent_doc_number] => 11447557 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-20 [patent_title] => Antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 15/781043 [patent_app_country] => US [patent_app_date] => 2016-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 27 [patent_no_of_words] => 53888 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 255 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15781043 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18117544 [patent_doc_number] => 11548925 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-10 [patent_title] => CACNA1H-derived tumor antigen polypeptide and use thereof [patent_app_type] => utility [patent_app_number] => 16/338126 [patent_app_country] => US [patent_app_date] => 2016-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 8749 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16338126 [rel_patent_id] =>[rel_patent_doc_number] =>)